Protocol Number: 00-C-0069
Patients with peritoneal cancer whose tumor is confined to the abdomen may be eligible for this study. Candidates will be screened with a medical history and physical examination including blood tests, electrocardiogram, and possibly bone scan, brain magnetic resonance imaging, and chest, abdomen and pelvic CT scans. Those enrolled in the study will undergo surgery to remove as much tumor as possible. Part of the intestines, pancreas, stomach or the entire spleen may also be removed if they are affected. During surgery, after the tumor has been removed, two catheters (thin plastic tubes) will be placed in the abdomen. A chemotherapy solution containing the anti-cancer drug cisplatin heated to a temperature of about 108.6 degrees (10 degrees above normal body temperature) will then be delivered into the abdomen through one catheter and drained through another. After 90 minutes of bathing the abdomen with this solution, the drug will be rinsed from the abdomen and the catheters removed. Another small catheter will then be placed and left inside the abdomen with one end coming out through the skin. Two to 10 days after the operation, the drugs fluorouracil (5-FU) and paclitaxel will be given through this catheter. After complete recovery from the surgery, the catheter will be removed and the patient discharged from the hospital. Clinic visits will be scheduled for periodic follow-up examination and tests. Patients in this study will also be asked to assess how this therapy affects their general health and well being. This will require filling out two quality-of-life questionnaires before surgery and again at each follow-up visit after surgery. Each questionnaire takes about 15 minutes to complete.
Search The Studies | Help | Questions |
Warren Grant Magnuson Clinical Center (CC) |
||